Predictors of Future Overdose Among People Who Inject Drugs in Baltimore, Maryland

Overview

Journal Drug Alcohol Depend Rep

Specialty Psychiatry

Date 2024 Oct 21

PMID 39430605

Authors

Michael P Ramirez

Gregory M Lucas

Kathleen R Page

Katie Zook

Miles Landry

Amanda Rosecrans

Robert Harris

Suzanne M Grieb

Oluwaseun Falade-Nwulia

William Clarke

Susan G Sherman

Brian W Weir

Affiliations

Soon will be listed here.

Abstract

Background: Longitudinal studies of future overdose risk among people who inject drugs (PWID) are needed to inform planning of targeted overdose preventions in the United States.

Methods: The Integrating Services to Improve Treatment and Engagement (INSITE) study followed 720 PWID between June 2018 and August 2019 to evaluate the delivery of mobilized healthcare services in Baltimore, Maryland. The present analyses used logistic regression to identify baseline characteristics predictive of non-fatal or fatal overdose during the 6-month follow-up among 507 participants with overdose information. Non-fatal overdoses were self-reported and fatal overdoses were identified through the National Death Index.

Results: At baseline, 121 (23 %) reported an overdose in the prior 6 months. Between baseline and follow-up, 66 (13 %) participants reported a non-fatal overdose and 6 (1 %) experienced a fatal overdose. Overdose during follow-up was positively associated with overdose in the 6 months prior to baseline (6.70 aOR; 95 % CI: 3.51, 12.78) and more than 6 months prior to baseline (2.49 aOR; 95 % CI: 1.52, 4.08) versus no prior overdose. Overdose during follow-up was also positively associated with buprenorphine treatment (2.37 aOR; CI: 1.08, 5.21) and negatively associated with non-prescribed methadone at baseline (0.59 aOR; 0.38, 0.93).

Conclusions: Identifying and intervening with PWID who experienced a recent overdose could reduce short-term elevated risk of future overdose. However, as other PWID reported never experiencing an overdose at baseline nonetheless experienced an overdose during follow-up, targeted approaches should be complemented with population-level interventions. Overdose risk implications of buprenorphine treatment and non-prescribed methadone are also discussed.

References

Snowdon J . Drug overdose death rates in different countries: Who should be alarmed?. Australas Psychiatry. 2022; 30(1):26-30. DOI: 10.1177/10398562221075192. View

Pearce N . Epidemiology in a changing world: variation, causation and ubiquitous risk factors. Int J Epidemiol. 2011; 40(2):503-12. DOI: 10.1093/ije/dyq257. View

Rouhani S, White R, Park J, Sherman S . High willingness to use overdose prevention sites among female sex workers in Baltimore, Maryland. Drug Alcohol Depend. 2020; 212:108042. PMC: 9426862. DOI: 10.1016/j.drugalcdep.2020.108042. View

G Verstraete A . Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit. 2004; 26(2):200-5. DOI: 10.1097/00007691-200404000-00020. View

Herring A, Vosooghi A, Luftig J, Anderson E, Zhao X, Dziura J . High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. JAMA Netw Open. 2021; 4(7):e2117128. PMC: 8283555. DOI: 10.1001/jamanetworkopen.2021.17128. View

Park J, Weir B, Allen S, Chaulk P, Sherman S . Fentanyl-contaminated drugs and non-fatal overdose among people who inject drugs in Baltimore, MD. Harm Reduct J. 2018; 15(1):34. PMC: 6034235. DOI: 10.1186/s12954-018-0240-z. View

McNeil R, Small W, Wood E, Kerr T . Hospitals as a 'risk environment': an ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs. Soc Sci Med. 2014; 105:59-66. PMC: 3951660. DOI: 10.1016/j.socscimed.2014.01.010. View

Kahan B, Forbes G, Ali Y, Jairath V, Bremner S, Harhay M . Increased risk of type I errors in cluster randomised trials with small or medium numbers of clusters: a review, reanalysis, and simulation study. Trials. 2016; 17(1):438. PMC: 5013635. DOI: 10.1186/s13063-016-1571-2. View

Solomon K, OConnor J, Gibbons J, Kilaru A, Feder K, Xue L . Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge. JAMA Health Forum. 2023; 4(3):e230245. PMC: 10313142. DOI: 10.1001/jamahealthforum.2023.0245. View

10.

Kelty E, Hulse G . Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone. Int J Drug Policy. 2017; 46:54-60. DOI: 10.1016/j.drugpo.2017.05.039. View

11.

Genberg B, Gicquelais R, Astemborski J, Knight J, Buresh M, Sun J . Trends in fatal and nonfatal overdose by race among people who inject drugs in Baltimore, Maryland from 1998 to 2019. Drug Alcohol Depend. 2021; 229(Pt B):109152. PMC: 8665116. DOI: 10.1016/j.drugalcdep.2021.109152. View

12.

Chambers L, Hallowell B, Zullo A, Paiva T, Berk J, Gaither R . Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl. JAMA Netw Open. 2023; 6(9):e2334540. PMC: 10507490. DOI: 10.1001/jamanetworkopen.2023.34540. View

13.

Schneider K, Park J, Allen S, Weir B, Sherman S . Patterns of polysubstance use and overdose among people who inject drugs in Baltimore, Maryland: A latent class analysis. Drug Alcohol Depend. 2019; 201:71-77. PMC: 6686197. DOI: 10.1016/j.drugalcdep.2019.03.026. View

14.

Dayton L, Tobin K, Falade-Nwulia O, Davey-Rothwell M, Al-Tayyib A, Saleem H . Racial Disparities in Overdose Prevention among People Who Inject Drugs. J Urban Health. 2020; 97(6):823-830. PMC: 7704879. DOI: 10.1007/s11524-020-00439-5. View

15.

Johnson B, Richert T . Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities. Harm Reduct J. 2019; 16(1):31. PMC: 6498489. DOI: 10.1186/s12954-019-0301-y. View

16.

Lewis D, Park J, Vail L, Sine M, Welsh C, Sherman S . Evaluation of the Overdose Education and Naloxone Distribution Program of the Baltimore Student Harm Reduction Coalition. Am J Public Health. 2016; 106(7):1243-6. PMC: 4984772. DOI: 10.2105/AJPH.2016.303141. View

17.

Motavalli D, Taylor J, Childs E, Valente P, Salhaney P, Olson J . "Health Is on the Back Burner:" Multilevel Barriers and Facilitators to Primary Care Among People Who Inject Drugs. J Gen Intern Med. 2020; 36(1):129-137. PMC: 7858998. DOI: 10.1007/s11606-020-06201-6. View

18.

Hadland S, Levy S . Objective Testing: Urine and Other Drug Tests. Child Adolesc Psychiatr Clin N Am. 2016; 25(3):549-65. PMC: 4920965. DOI: 10.1016/j.chc.2016.02.005. View

19.

Samuels E, Bailer D, Yolken A . Overdose Prevention Centers: An Essential Strategy to Address the Overdose Crisis. JAMA Netw Open. 2022; 5(7):e2222153. DOI: 10.1001/jamanetworkopen.2022.22153. View

20.

Wakeman S, Larochelle M, Ameli O, Chaisson C, McPheeters J, Crown W . Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020; 3(2):e1920622. PMC: 11143463. DOI: 10.1001/jamanetworkopen.2019.20622. View